Pular para o conteúdo
Merck

Upregulation of GPR109A in Parkinson's disease.

PloS one (2014-10-21)
Chandramohan Wakade, Raymond Chong, Eric Bradley, Bobby Thomas, John Morgan
RESUMO

Anecdotal animal and human studies have implicated the symptomatic and neuroprotective roles of niacin in Parkinson's disease (PD). Niacin has a high affinity for GPR109A, an anti-inflammatory receptor. Niacin is also thought to be involved in the regulation of circadian rhythm. Here we evaluated the relationships among the receptor, niacin levels and EEG night-sleep in individuals with PD. GPR109A expression (blood and brain), niacin index (NAD-NADP ratio) and cytokine markers (blood) were analyzed. Measures of night-sleep function (EEG) and perceived sleep quality (questionnaire) were assessed. We observed significant up-regulation of GPR109A expression in the blood as well as in the substantia nigra (SN) in the PD group compared to age-matched controls. Confocal microscopy demonstrated co-localization of GPR109A staining with microglia in PD SN. Pro and anti-inflammatory cytokines did not show significant differences between the groups; however IL1-β, IL-4 and IL-7 showed an upward trend in PD. Time to sleep (sleep latency), EEG REM and sleep efficiency were different between PD and age-matched controls. Niacin levels were lower in PD and were associated with increased frequency of experiencing body pain and decreased duration of deep sleep. The findings of associations among the GPR109A receptor, niacin levels and night-sleep function in individuals with PD are novel. Further studies are needed to understand the pathophysiological mechanisms of action of niacin, GPR109A expression and their associations with night-sleep function. It would be also crucial to study GPR109A expression in neurons, astrocytes, and microglia in PD. A clinical trial to determine the symptomatic and/or neuroprotective effect of niacin supplementation is warranted.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
βß-Nicotinamida adenina dinucleotídeo fosfato
Sigma-Aldrich
β-Dinucleotídeo de nicotinamida adenina, ≥95% (HPLC)
Sigma-Aldrich
β-Dinucleotídeo de nicotinamida adenina, Grade AA-1
Sigma-Aldrich
β-Dinucleotídeo de nicotinamida adenina, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide, pkg of 10 mg (per vial)
Sigma-Aldrich
β-Dinucleotídeo de nicotinamida adenina, ≥99%
Sigma-Aldrich
β-Dinucleotídeo de nicotinamida adenina, suitable for cell culture, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide, pkg of 50 mg (per vial)
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide, pkg of 20 mg (per vial)
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide phosphate sodium salt, pkg of 5 mg (per vial)
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide lithium salt from Saccharomyces cerevisiae, ≥95%
Sigma-Aldrich
β-Dinucleotídeo de nicotinamida adenina, ≥98%, BioUltra, from yeast
Sigma-Aldrich
β-Dinucleotídeo de nicotinamida adenina, purified by column chromatography, ≥99%
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide phosphate sodium salt, pkg of 10 mg (per vial)